Bio-Rad Laboratories, Inc. (BIO)

Market Cap	6.81B -2.7%
Revenue (ttm)	2.59B +1.9%
Net Income	168.80M
EPS	6.24
Shares Out	26.76M
PE Ratio	40.75
Forward PE	25.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,808
Open	256.41
Previous Close	257.32
Day's Range	251.32 - 258.81
52-Week Range	211.43 - 343.12
Beta	1.06
Analysts	Buy
Price Target	327.25 (+28.68%)
Earnings Date	Apr 30, 2026

About BIO

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 7,450
• Stock Exchange: NYSE
• Ticker Symbol: BIO
• Website: https://www.bio-rad.com

Analyst Summary

According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price target is $327.25, which is an increase of 28.68% from the latest price.

Price Target

$327.25

(28.68% upside)

Analyst Consensus: Buy